← Entera Bio Ltd. (ENTX) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Entera Bio Ltd. (ENTX)
Biological Products, (No Diagnostic Substances) · market cap $485M · as of 2026-07-16
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-13 (est.)
Earnings
Pipeline
3
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Entera Bio Ltd. (ENTX) is a small-cap biotech with an $80M market cap developing EB612 (EBP05), an oral parathyroid hormone (1-34) formulation in Phase 2 for hypoparathyroidism. The company is in a critical financial position with only $4.1M cash and roughly 4 months of runway, creating acute near-term capital risk. With zero revenue historically and a single analyst covering the stock at a $9 target, this is a high-risk, binary-outcome micro-cap.
The catalyst path
- 2026-11-13 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| EB612 (EBP05) | Phase 2 | Hypoparathyroidism |
| EBP05 | Phase 2 | Hypoparathyroidism |
| EnteraBio's Oral Parathyroid Hormone (1-34) | Phase 2 | Hypoparathyroidism |
Price & technical context
3-month
+68.1%
6-month
+166.0%
12-month
+52.2%
52-wk range
$1.00–$3.92
vs 50-day MA
-4.8%
vs 200-day MA
+53.5%
Realized vol
110.2%
Max drawdown
-68.2%
Daily closes through 2026-09-25. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for ENTX (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.